Biomedical Engineering Reference
In-Depth Information
56. Vernooy JH, Kucukaycan M, Jacobs JA, Chavannes NH, Buurman WA,
Dentener MA, et al. Local and systemic inflammation in patients with chronic
obstructive pulmonary disease: soluble tumor necrosis factor receptors are
increased in sputum. Am J Respir Crit Care Med 2002; 166:1218-1224.
57. de Godoy I, Donahoe M, Calhoun WJ, Mancino J, Rogers RM. Elevated
TNF-
a
production by peripheral blood monocytes of weight-losing COPD
patients. Am J Respir Crit Care Med 1996; 153:633-637.
58. Reimold AM. TNFalpha as therapeutic target: new drugs, more applications.
Curr Drug Targets Inflamm Allergy 2002; 1:377-392.
59. Rabinowitz MH, Andrews RC, Becherer JD, Bickett DM, Bubacz DG,
Conway JG, et al. Design of selective and soluble inhibitors of tumor necrosis
factor-alpha converting enzyme (TACE). J Med Chem 2001; 44:4252-4267.
60. Sturton G, Fitzgerald M. Phosphodiesterase 4 inhibitors for the treatment of
COPD. Chest 2002; 121:192S-196S.
61. Compton CH, Gubb J, Nieman R, Edelson J, Amit O, Bakst A, et al. Cilomi-
last, a selective phosphodiesterase-4 inhibitor for treatment of patients with
chronic obstructive pulmonary disease: a randomised, dose-ranging study.
Lancet 2001; 358:265-270.
62. Gamble E, Grootendorst DC, Brightling CE, Troy S, Qui Y, Zhu J, et al.
Anti-inflammatory effects of the phosphodiesterase 4 inhibitor cilomilast
(Ariflo) in COPD. Am J Respir Crit Care Med 2003; 168:976-982.
63. Houslay MD, Adams DR. PDE4 cAMP phosphodiesterases: modular
enzymes that orchestrate signalling cross-talk, desensitization and compart-
mentalization. Biochem J 2003; 370:1-18.
64. Lamontagne S, Meadows E, Luk P, Normandin D, Muise E, Boulet L, et al.
Localization of phosphodiesterase-4 isoforms in the medulla and nodose
ganglion of the squirrel monkey. Brain Res 2001; 920:84-96..
65. Robichaud A, Stamatiou PB, Jin SL, Lachance N, MacDonald D, Laliberte F,
et al. Deletion of phosphodiesterase 4D in mice shortens a2-adrenoceptor-
mediated anesthesia, a behavioral correlate of emesis. J Clin Invest 2002;
110:1045-1052.
66. Jin SL, Conti M. Induction of the cyclic nucleotide phosphodiesterase PDE4B
is essential for LPS-activated TNF-alpha responses. Proc Natl Acad Sci USA
2002; 99:7628-7633.
67. Kuss H, Hoefgen N, Johanssen S, Kronbach T, Rundfeldt C. In vivo efficacy
in airway disease models of N-(3,5-dichloropyrid-4-yl)-[l-(4-fluorobenzyl]-5-
hydroxy-indole-3-yl)-glyoxylic acid amide (AWD 12-281), a selective phos-
phodiesterase 4 inhibitor for inhaled administration. J Pharmacol Exp Ther
2003; 307:373-385.
68. Di Stefano A, Caramon G, Capelli A, Lusuardi M, Gnemmi I, Ioli F, et al.
Increased expression of NF-
k
B in bronchial biopsies from smokers and
patients with COPD. Eur Respir J 2002; 20:556-563.
69. Caramon G, Romagnoli M, Casolari P, Bellettato C, Casoni G, Boschetto P,
et al. Nuclear localization of p65 in sputum macrophages but not in sputum
neutrophils during COPD exacerbations. Thorax 2003; 58:348-351.
70. Delhase M, Li N, Karin M. Kinase regulation in inflammatory response.
Nature 2000; 406:367-368.
